LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

LLY

775.79

-0.45%↓

JNJ

155.7

+2.05%↑

NVO

69.84

+1.19%↑

ABBV

189.81

+2.22%↑

UNH

325.71

+4.47%↑

Search

GlycoMimetics Inc

Geschlossen

BrancheGesundheitswesen

0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.13

Max

0.15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.3B

-2.3B

EPS

-0.04

Gewinnspanne

-13,354.199

Angestellte

4

EBITDA

2.9M

-2.4M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+43.79% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

10M

Vorheriger Eröffnungskurs

0.15

Vorheriger Schlusskurs

0.15

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

GlycoMimetics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2025, 23:49 UTC

Ergebnisse

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. Juni 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. Juni 2025, 21:30 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. Juni 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. Juni 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. Juni 2025, 23:30 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. Juni 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. Juni 2025, 23:19 UTC

Akquisitionen, Fusionen, Übernahmen

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. Juni 2025, 22:06 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:15 UTC

Ergebnisse

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. Juni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 20:52 UTC

Ergebnisse

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. Juni 2025, 20:51 UTC

Ergebnisse

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

GlycoMimetics Inc Prognose

Kursziel

By TipRanks

43.79% Vorteil

12-Monats-Prognose

Durchschnitt 22 USD  43.79%

Hoch 22 USD

Tief 22 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für GlycoMimetics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

0.2416 / 0.261Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

$

Über GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.